Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

Nymox Pharmaceutical (NASDAQ:NYMX) reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.
As quoted in the press release:

According to the new publication, “In conclusion, data from these 4 U.S. studies show statistically significant long-term improvement in BPH symptoms and objective outcomes including significant reduction in spontaneous AUR as well as the addition of BPH surgery;” and “FT is well tolerated with an excellent safety profile. Hence, FT is a safe and efficacious clinic based treatment for BPH involving an intraprostatic injection that requires only a few minutes to administer, with no catheter nor anesthesia requirements. FT injectable represents a novel, first in class BPH treatment modality.”

Click here to read the full press release.